Physician Assistant Program year 2025 Reported 2023–2025 Source: CMS Open Payments, 2026 publication

Karina Patel

Physician Assistant Georgetown, TX Physician Assistant

NPI 1154006203 CMS profile 11510436

204 S Interstate 35 Ste 103, Georgetown, TX 78628

Open in the dashboard

General payments

$15,560

428 records reported · program years 2023–2025

Research payments

$0

Paid to them · None reported · program years 2023–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Karina Patel of Georgetown, TX is reported in the CMS Open Payments database as having received $15,560 across 428 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $9,295 226
2024 General $5,127 161
2023 General $1,138 41

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Karina Patel
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Karina Patel were reported at $9,295. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Karina Patel Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $0 $132 $37–$438 $132
2022 $0 $155 $48–$522 $149
2023 $1,138 $167 $52–$557 $160
2024 $5,127 $178 $55–$600 $164
2025 $9,295 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2023–2025
  1. Merz Pharmaceuticals, LLC $4,162 143 payments
  2. AbbVie, Inc. $2,785 36 payments
  3. Amneal Pharmaceuticals LLC $1,875 26 payments
  4. Medtronic, Inc. $1,612 12 payments
  5. Abbott Laboratories $1,148 41 payments
  6. Teva Pharmaceuticals USA, Inc. $810 38 payments
  7. Neurocrine Biosciences, Inc. $636 38 payments
  8. Boston Scientific Corporation $619 4 payments
  9. ACADIA Pharmaceuticals Inc $609 28 payments
  10. US WorldMeds, LLC $322 21 payments
  11. Other $980 41 payments

Every payment, record by record

What the payments were for General payments · program years 2023–2025
  1. Food and Beverage $10,558 406 payments
  2. Consulting Fee $2,779 6 payments
  3. Travel and Lodging $2,093 14 payments
  4. Education $129 2 payments
Products named General payments · program years 2023–2025
  1. Xeomin $3,712 125 payments
  2. VYALEV $2,153 15 payments
  3. PERCEPT PC BRAINSENSE $1,612 12 payments
  4. RYTARY $1,457 10 payments
  5. Austedo XR $708 35 payments
  6. INGREZZA $636 38 payments
  7. INFINITY Neuromodulation $635 14 payments
  8. Vercise $619 4 payments
  9. NUPLAZID $609 28 payments
  10. INFINITY Structural Heart $513 27 payments
  11. Other $2,970 119 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 34 drugs

Part D claims

1,604

Median for Physician Assistant: 241

Drug cost

$1,412,012

Median for Physician Assistant: $4,110

Branded share of claims

60.8%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Nuplazid Pimavanserin Tartrate Brand 66 $410,152
Rytary Carbidopa/Levodopa Brand 149 $264,425
Austedo Deutetrabenazine Brand 19 $219,195
Nourianz Istradefylline Brand 51 $154,569
Inbrija Levodopa Brand 21 $100,490
Horizant Gabapentin Enacarbil Brand 37 $56,693
Ongentys Opicapone Brand 39 $56,380
Gocovri Amantadine Hcl Brand 17 $38,145
Neupro Rotigotine Brand 13 $23,411
Nuedexta Dextromethorphan Hbr/Quinidine Brand 12 $21,917

The 10 drugs with the highest cost, of 34 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 11 billing codes

Paid by Medicare

$11,441

Medicare's payments for the services billed

Medicare patients

80

Average age 76

Services billed

195

40 women, 40 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 70%
Arthritis 50%
Depression 38%
Ischemic heart disease 28%
Osteoporosis 23%
Cancer 20%
Diabetes 19%
Atrial fibrillation 18%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 14 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
RYTARY
  • Amneal Pharmaceuticals LLC $1,457
$1,457 149 —
Xeomin
  • Merz Pharmaceuticals, LLC $1,237
$1,237 — —
Austedo XR
  • Teva Pharmaceuticals USA, Inc. $357
$357 19 —
DUOPA
  • AbbVie, Inc. $355
$355 — —
INGREZZA
  • Neurocrine Biosciences, Inc. $320
$320 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 14 in the dashboard with a free account

Records

428 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record